No: PureVida will not prevent, treat, or cure breast cancer†. Limited clinical trial evidence indicates that PureVida might lower elevated C-reactive protein (CRP) levels in women who have survived breast cancer. In addition, the same clinical trial indicates that PureVida may reduce joint pain associated with aromatase inhibitor (AI) therapy, which is often prescribed as part of a long-term prevention of recurrence regimen to breast cancer survivors†.
Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection, and tissue damage. PureVida is formulated to support the body’s natural response to chronic inflammation. Several published human studies conducted in Denmark, the U.S., and China have reported an association, in certain subsets of women evaluated over time, between lower CRP levels and long-term breast health.
For many women who have survived breast cancer, staying on prescribed aromatase inhibitor therapy is considered critical to their long-term health; adherence to AI therapy is difficult for many due to the joint pain that is a typical side effect of the therapy.
Maintaining a healthy heart is critical as heart disease is often a high risk for women who have survived breast cancer. PureVida provides 2 key element of the Mediterranean heart healthy diet, omega-3s and olive polyphenols. Two PureVida softgels taken daily for a week provide the equivalent amount of olive polyphenols (hydroxytyrosol and tyrosol) as 2.5 liters of olive oil per week without the added calories or unwanted fats. Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. PureVida contains a minimum of 450 mg of EPA and 300 mg of DHA†.
Because only one non-blinded trial, with 45 participants, has been performed††, more research is needed to confirm that PureVida reduces levels of CRP or joint pain.